Key Points
- Director Leslie Norwalk sold 2,000 shares of Globus Medical on Jan. 8 at an average price of $101.10 for $202,200, reducing her direct holdings to 10,419 shares (a 16.10% decrease); the sale was disclosed in an SEC filing.
- Globus beat expectations in its latest quarter with EPS of $1.18 vs. $0.79 expected and revenue of $769.05 million (up 22.9% year-over-year), and the company set FY2025 guidance of 3.75–3.85 EPS.
- Market sentiment is broadly positive: the stock has a market cap of $12.28 billion and a P/E of 29.6, carries a consensus rating of "Moderate Buy" with an average target of $97.78, and recently traded near its 1‑year high of $101.40.
Globus Medical, Inc. (NYSE:GMED - Get Free Report) Director Leslie Norwalk sold 2,000 shares of Globus Medical stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $202,200.00. Following the transaction, the director directly owned 10,419 shares in the company, valued at $1,053,360.90. This represents a 16.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Globus Medical Price Performance
NYSE GMED opened at $91.75 on Tuesday. The company has a fifty day moving average price of $86.41 and a 200-day moving average price of $68.25. The firm has a market cap of $12.28 billion, a price-to-earnings ratio of 29.60, a PEG ratio of 1.58 and a beta of 1.06. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40.
Globus Medical (NYSE:GMED - Get Free Report) last released its quarterly earnings results on Thursday, November 6th. The medical device company reported $1.18 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.39. The business had revenue of $769.05 million for the quarter, compared to analysts' expectations of $734.58 million. Globus Medical had a net margin of 15.30% and a return on equity of 11.52%. The firm's revenue for the quarter was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company earned $0.83 earnings per share. Globus Medical has set its FY 2025 guidance at 3.750-3.85 EPS. On average, research analysts anticipate that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.
Institutional Investors Weigh In On Globus Medical
Large investors have recently added to or reduced their stakes in the company. Alliancebernstein L.P. raised its stake in Globus Medical by 1,303.9% in the 3rd quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company's stock valued at $117,700,000 after acquiring an additional 1,908,795 shares during the period. Boston Trust Walden Corp bought a new stake in shares of Globus Medical in the third quarter valued at approximately $67,891,000. Norges Bank purchased a new stake in shares of Globus Medical during the 2nd quarter valued at approximately $68,038,000. ANTIPODES PARTNERS Ltd boosted its holdings in Globus Medical by 49,020.3% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company's stock worth $51,034,000 after buying an additional 889,229 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Globus Medical by 72.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,011,104 shares of the medical device company's stock worth $115,166,000 after buying an additional 842,547 shares during the period. Hedge funds and other institutional investors own 95.16% of the company's stock.
Analyst Ratings Changes
Several research analysts have weighed in on GMED shares. Weiss Ratings reissued a "hold (c)" rating on shares of Globus Medical in a research report on Wednesday, October 8th. Morgan Stanley lifted their target price on Globus Medical from $70.00 to $100.00 and gave the stock an "overweight" rating in a research note on Tuesday, December 2nd. Canaccord Genuity Group boosted their price target on shares of Globus Medical from $105.00 to $112.00 and gave the stock a "buy" rating in a report on Friday. Royal Bank Of Canada raised their price objective on shares of Globus Medical from $92.00 to $100.00 and gave the stock an "outperform" rating in a report on Wednesday, December 17th. Finally, Wall Street Zen raised shares of Globus Medical from a "buy" rating to a "strong-buy" rating in a research report on Saturday, January 3rd. Eight equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. According to MarketBeat, Globus Medical currently has a consensus rating of "Moderate Buy" and an average target price of $97.78.
Get Our Latest Report on GMED
About Globus Medical
(
Get Free Report)
Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.
In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
